Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rodolfo Savica

Showing results (11-20 of 224) with videos related to

Pageof 23
Sort By:
Neurology|July 30, 2024
What Is the Role of Glucagon-Like Peptide 1 Signaling in the Nervous System and Its Potential Neuroprotective Effects?Pierpaolo Turcano, Rodolfo Savica, Eduardo Benarroch
Parkinsonism & Related Disorders|January 7, 2018
Hyperglycemic chorea/ballism ascertained over 15 years at a referral medical centerConor Ryan, J Eric Ahlskog, Rodolfo Savica
Archives of Neurology|July 14, 2010
When does Parkinson disease start?Rodolfo Savica, Walter A Rocca, J Eric Ahlskog
Journal of Neurology|March 15, 2011
Ifosfamide associated myoclonus-encephalopathy syndromeRodolfo Savica, Alejandro A Rabinstein, Keith A Josephs
Neurology. Genetics|April 29, 2016
Familial aggregation of Parkinson disease in Utah: A population-based analysis using death certificatesRodolfo Savica, Lisa A Cannon-Albright, Stefan Pulst
JAMA Neurology|February 21, 2018
When Do α-Synucleinopathies Start? An Epidemiological Timeline: A ReviewRodolfo Savica, Bradley F Boeve, Michelle M Mielke
JAMA Neurology|October 18, 2016
Trends in the Incidence of Parkinson Disease-ReplyWalter A Rocca, Rodolfo Savica, Brandon R Grossardt
Neurology|April 1, 2021
Physical Activity May Reduce Apolipoprotein E4-Associated Cognitive Decline in Parkinson DiseaseJacob Raber, Sirwan K L Darweesh, Rodolfo Savica
JAMA Neurology|August 15, 2018
Orthostatic Hypotension as a Prodromal Marker of α-Synucleinopathies-ReplyRodolfo Savica, Bradley F Boeve, Michelle M Mielke
Brain Sciences|March 27, 2019
Parkinsonism Risk Factors in Salt Lake City, Utah: A Community-Based StudyDavid Shprecher, Nan Zhang, Matthew Halverson, et al.
Pageof 23

Showing results (11-20 of 224) with videos related to

Sort By:
Pageof 23
Neurology|July 30, 2024
What Is the Role of Glucagon-Like Peptide 1 Signaling in the Nervous System and Its Potential Neuroprotective Effects?Pierpaolo Turcano, Rodolfo Savica, Eduardo Benarroch
Parkinsonism & Related Disorders|January 7, 2018
Hyperglycemic chorea/ballism ascertained over 15 years at a referral medical centerConor Ryan, J Eric Ahlskog, Rodolfo Savica
Archives of Neurology|July 14, 2010
When does Parkinson disease start?Rodolfo Savica, Walter A Rocca, J Eric Ahlskog
Journal of Neurology|March 15, 2011
Ifosfamide associated myoclonus-encephalopathy syndromeRodolfo Savica, Alejandro A Rabinstein, Keith A Josephs
Neurology. Genetics|April 29, 2016
Familial aggregation of Parkinson disease in Utah: A population-based analysis using death certificatesRodolfo Savica, Lisa A Cannon-Albright, Stefan Pulst
JAMA Neurology|February 21, 2018
When Do α-Synucleinopathies Start? An Epidemiological Timeline: A ReviewRodolfo Savica, Bradley F Boeve, Michelle M Mielke
JAMA Neurology|October 18, 2016
Trends in the Incidence of Parkinson Disease-ReplyWalter A Rocca, Rodolfo Savica, Brandon R Grossardt
Neurology|April 1, 2021
Physical Activity May Reduce Apolipoprotein E4-Associated Cognitive Decline in Parkinson DiseaseJacob Raber, Sirwan K L Darweesh, Rodolfo Savica
JAMA Neurology|August 15, 2018
Orthostatic Hypotension as a Prodromal Marker of α-Synucleinopathies-ReplyRodolfo Savica, Bradley F Boeve, Michelle M Mielke
Brain Sciences|March 27, 2019
Parkinsonism Risk Factors in Salt Lake City, Utah: A Community-Based StudyDavid Shprecher, Nan Zhang, Matthew Halverson, et al.
Pageof 23